期刊文献+

桃红四物汤对膝关节骨折患者血沉,CRP及TNF-α水平的影响及其临床疗效 被引量:18

Effects of Taohong Siwu Decoction on Levels of Erythrocyte Sedimentation Rate, CRP and TNF-α in Patients with Knee Fractures and Its Clinical Efficacy
原文传递
导出
摘要 目的:探讨桃红四物汤在膝关节骨折中的应用及对血沉、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)的影响。方法:112例膝关节骨折患者按抽签法分为对照组与实验组,各56例,对照组予以常规治疗,实验组基于对照组加用桃红四物汤治疗,比较两组血沉,CRP、TNF-α、白细胞介素-1(IL-1),红细胞比积、血浆黏度、全血低切黏度、全血高切黏度,中医症候积分,膝关节功能。结果:实验组血沉,CRP、TNF-α、IL-1、红细胞比积、血浆黏度、全血低切黏度、全血高切黏度低于对照组(P<0.05)。实验组中医症候积分低于对照组(P<0.05)。实验组膝关节功能优良率高于对照组(P<0.05)。结论:桃红四物汤可促进膝关节功能的恢复,降低血沉、CRP、TNF-α水平,值得推广。 Objective:To research the application of taohong siwu decoction in treatment of knee fractures and the influence on serum levels of erythrocyte sedimentation rate,c-reactive protein (CRP) and tumor necrosis factor-α (TNF-o).Methods:112 cases with knee fractures who were treated in our hospital were selected and divided into the control group and the experimental group,with 56 cases in each group.The patients in the control group were treated with conventional method,while the patients in the experimental group were treated with taohong siwu decoction on the basis of the control group.Then the erythrocyte sedimentation rate,CRP,TNF-α,interleukin-1 (IL-1),red blood cells,plasma viscosity,whole blood low shear viscosity,whole blood high shear viscosity,TCM symptoms integral and the knee functions of patients were observed and compared between the two groups before and after the treatment.Results:The erythrocyte sedimentation rate,CRP,TNF-α,IL-1,red blood cells,plasma viscosity,whole blood low shear viscosity and whole blood high shear viscosity of the experimental group were lower than those of the control group (P〈0.05).The TCM symptom score of the experimental group was lower than that of the control group (P〈0.05).The knee functions of the experimental group was higher than that of the control group (P〈0.05).Conclusions:Taohong siwu decoction can promote the knee functions and reduce the levels of blood sedimentation,CRP and TNF-α,which is worthy of clinical application.
出处 《现代生物医学进展》 CAS 2017年第19期3726-3729,共4页 Progress in Modern Biomedicine
基金 四川省教育厅科研项目(08ZA112)
关键词 膝关节骨折 桃红四物汤 血沉 C反应蛋白 肿瘤坏死因子-Α TNF-Α Knee fracture Taohong siwu decoction Blood sedimentation C-reactive protein
  • 相关文献

参考文献2

二级参考文献19

  • 1Amy SC,Linda TV. Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome:etiology and emerging therapies[J].Support Cancer Therapy,2004,(4):213-218.
  • 2Yuichiro A,Kojiro H,Kimie S. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer[J].Biol Pharm Bull,2012,(5):717-724.
  • 3Thomas CW,Yang C,Peter RG. Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously[J].Oncol Lett,2012,(6):1191-1194.
  • 4Vivian VG,Heidi F,Nancy F. A double-blind,randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients[J].{H}CANCER,2010,(20):4735-4743.
  • 5Sherry LW,Rui Q,Smitha P. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced Hand-Foot Syndrome:North central cancer treatment group study N05C5[J].{H}Journal of Clinical Oncology,2010,(35):5182-5187.
  • 6Kang YK,Lee SS,Yoon DH. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy:results of a randomized,doubleblind,placebo-controlled study[J].{H}Journal of Clinical Oncology,2010,(24):3824-3829.
  • 7Vail DM,Chun R,Thamm DH. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes:a randomized,double-blind clinical trial using a canine model[J].{H}Clinical Cancer Research,1998,(6):1567-1571.
  • 8Yoshimoto N,Yamashita T,Fujita T. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer[J].{H}Breast Cancer,2010,(4):298-302.
  • 9Blum JL,Jones SE,Buzdar AU. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer[J].{H}Journal of Clinical Oncology,1999,(2):485-493.
  • 10Vincent S,Florence D,Christine C. HFS-14,a specific quality of life scale developed for patients suffering from hand-foot syndrome[J].{H}Oncologist(the)t,2011,(10):1469-1478.

共引文献24

同被引文献159

引证文献18

二级引证文献133

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部